TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02527499

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ride-On Cars with Bimanual Training Program (ROCBT)
Description: The car driving training includes 2 phases: I-car exploration and II-prompted driving. Participants can learn how to move and stop the car in the car exploration phase. Through prompted driving in phase II, they can use the car as a mean to explore environments (e.g., to the elevator, to different stores) and contact with people (e.g., drive to the caregiver and get the toy). Bimanual training involves activities which include perceptual motor tasks (e.g., smear both hands with color), holding and manipulative tasks (e.g., cutting toy vegetables or fruits), posture and balance (e.g., pull a cart), and self-care and activities of daily living (e.g., drinking water from a cup with two handles).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Early Mobility Training Program
Description: Most of the guidelines are similar with ROCBT, except for the bimanual training. The therapist and family will merely focus on independent mobility training and improving socialization. The training time and period is the same as ROCBT.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular Therapy Program
Description: The regular therapy group will continue the regular therapy, including physical, occupational and speech therapy. The general propose of the training is to improve the developmental scales, mobility, socialization and upper limb use in functional tasks. The research team will videotape the child's natural play and driving performance at the hospital for 1 hour/per session, 1 session/per week during the 9-week intervention phase.
Study: NCT01576874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 40 IUs of oxytocin administered intranasally one time

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo administered intranasally one time
Study: NCT01610739

Intervention type: DRUG
Group type: OTHER
Intervention: Indigocyanine green dye
Description: Each patient will receive 1 injection of indigocyanine green dye using 2.5 mg/mL concentration of the imaging agent. 3mL of this mixture will be injected intravenously, followed by 10mL NS bolus, just prior to imaging with the SPY scope
Study: NCT01081158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: SCH 900518 Biologic: Peginterferon alfa-2b(PegIntron)
Description: Drug: SCH 900518~Biologic: Peginterferon alfa-2b(PegIntron)~Period 1: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 7 days .~Period 2: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 14 days in combination with 1.5 µg/kg PegIntron administered subcutaneously weekly.
Study: NCT02726893

Intervention type: OTHER
Intervention: no intervention
Study: NCT04056871

Intervention type: DIAGNOSTIC_TEST
Intervention: Frailty Screening Tools
Description: This is an observational and prospective study of patients who are going for elective surgery, thus no intervention will be given.
Study: NCT04490317

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: 1. Cardiac MRI be taken to CO poisoned patients~2. Cardiac CT be taken to CO poisoned patients~3. TTE be taken to CO poisoned patients~4. Brain MRI be taken to CO poisoned patients~5. Neurocognitive function tests be taken to CO poisoned patients~6. Laboratory tests be taken to CO poisoned patients

Intervention type: PROCEDURE
Intervention: Hyperbaric oxygen therapy
Description: 1. Hyperbaric oxygen therapy be used for CO poisoned patients~2. Therapeutic hypothermia be used for CO poisoned patients
Study: NCT02220946

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Electrical Stimulation
Description: A vaginal probe inserted, and a medium frequency (50 Hz) alternating current was administered for 5 seconds on, 5 seconds off. the intensity of the current was started at 0 mA, and gradually increased until pelvic muscle contractions was observed, then increased according to patient tolerance. each patient received a 20 minute session once a week for total 8 session
Study: NCT02039466

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: volume controlled ventilation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pressure controlled ventilation
Study: NCT04375930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STANDARD STOMA CARE AND COMPLICATION DIAGNOSTIC ALGORITHM EDUCATION
Description: STANDARD STOMA CARE AND COMPLICATION DIAGNOSTIC ALGORITHM EDUCATION: It is consist of skills, discharge, compilation and algorithm education.
Study: NCT00218790

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cool Dialysate
Description: Decreased temperature of the dialysis bath
Study: NCT04375930

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: It consists of only skills and discharge education
Study: NCT02489019

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: Sodium chloride will be used as a placebo comparator in this trial
Study: NCT00898404

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01117012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Study: NCT02043236

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy bones pamphlet
Description: written educational material

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy bones pamphlet
Description: written educational material

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bone Health Care Coordinator
Description: The Bone Health Care Coordinator reviews educational materials with participant and facilitates ordering BMD.
Study: NCT01081158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: SCH 900518 Biologic: Peginterferon alfa-2b
Description: Drug: SCH 900518~Biologic: Peginterferon alfa-2b~Period 1: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 7 days~Period 2: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 14 days in combination with 1.5 µg/kg PegIntron administered subcutaneously weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: SCH 900518 Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)
Description: Drug: SCH 900518~Drug: Ritonavir (RTV)~Biologic: Peginterferon alfa-2b (PegIntron)~Period 1: Amorphous SCH 900518 (400 mg) or placebo BID administered as oral suspension + ritonavir (200 mg BID) (2-100 mg oral capsules) for 7 days.~Period 2: Amorphous SCH 900518 (400 mg) or placebo BID administered as oral suspension+ ritonavir (200 mg BID) (2-100 mg oral capsules) + PegIntron (1.5 µg/kg QW) for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: SCH 900518 Drug: Ritonavir (RTV) Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)
Description: Drug: SCH 900518~Drug: Ritonavir (RTV)~Biologic: Peginterferon alfa-2b (PegIntron)~Period 1, Amorphous SCH 900518 (400 mg) or placebo BID administered as an oral suspension + RTV (200 mg BID) oral capsules (2-100 mg capsules) for 7 days.~Period 2, SCH 900518 (400 mg) or placebo BID as an oral suspension + RTV (200 mg BID) oral capsules (2-100 mg capsules) +PegIntron (1.5 µg/kg SC QW) for 14 days.
Study: NCT02043236

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Letter to GP
Description: The letter to the General Practitioner contains information about the study, recommendations for bone health, guidelines of Osteoporosis Canada, and the identical educational material that the participant received.
Study: NCT02489019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl is a synthetic opioid analgesic that will be used as the experimental intervention in this trial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl is a synthetic opioid analgesic that will be used as the experimental intervention in this trial
Study: NCT04309214

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MCT fats
Description: Subjects will be asked to take 3 new MCT products for 7 days each over a 25 day period
Study: NCT03685045

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Campaign days
Description: Participants who consent will complete study procedures (Hep C test, fibroscan, questionnaire, clinical assessment) and followed up through medical record review.
Study: NCT00356057

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Protos DR/CLS and Stratos LV CRT pacemakers
Description: Protos DR/CLS is a dual chamber pacemaker with CLS rate adaption, Stratos LV is a biventricular pacemaker with accelerometer based rate adaption

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Protos DR/CLS and Stratos LV CRT pacemakers
Description: Protos DR/CLS is a dual chamber pacemaker with CLS rate adaption, Stratos LV is a biventricular pacemaker with accelerometer based rate adaption

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Protos DR/CLS and Stratos LV CRT pacemakers
Description: Protos DR/CLS is a dual chamber pacemaker with CLS rate adaption, Stratos LV is a biventricular pacemaker with accelerometer based rate adaption
Study: NCT04011124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: single dose on Day 1 and Day 12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: QD on Day 5-14 for 10 days
Study: NCT03516734

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron fortified lentils
Description: Lentils will be iron-fortified using NaFeEDTA iron fortificants

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non Iron-fortified lentils
Description: Non-fortified lentils will be provided

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Intake
Description: No lentils will be provided.
Study: NCT01888861

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: alpha-lipoic acid
Description: the patients in this arm receive 900mg alpha-lipoic acid through NG tube.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: the patients in this arm were received 900mg placebo through NG tube.
Study: NCT01254448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5619
Description: Group 1: 25 mg TC-5619 administered once daily for 28 days. Group 2: 50-150 mg TC-5619 administered once daily for 10 days.
Study: NCT00080886

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: rituximab

Intervention type: DRUG
Group type: OTHER
Intervention: carmustine

Intervention type: DRUG
Group type: OTHER
Intervention: cytarabine

Intervention type: DRUG
Group type: OTHER
Intervention: etoposide

Intervention type: DRUG
Group type: OTHER
Intervention: melphalan

Intervention type: PROCEDURE
Group type: OTHER
Intervention: autologous bone marrow transplantation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: peripheral blood stem cell transplantation
Study: NCT03485092

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 10 MG
Description: Empagliflozin 10mg tablets for oral self administration once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: placebo tablets for oral self administration once a day
Study: NCT03654755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN002
Description: Daily dose of ASN002 for up to 110 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN002
Description: Daily dose of ASN002 for up to 110 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN002
Description: Daily dose of ASN002 for up to 110 weeks
Study: NCT02551666

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance recovery training
Description: Participants will practice recovering their balance after a perturbation similar to tripping while walking. Each of these 'balance recovery training' sessions will last approximately 30 minutes, and will be performed 3 times per week for 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tai Chi exercise
Description: Participants will perform Tai Chi exercises (Yang short form) for 30 minutes, 3 times a week for 4 weeks. Each session will be led by an experienced Tai Chi instructor.
Study: NCT02563821

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patient Controlled Epidural Analgesia for third trimester termination of preganancy analgesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patient Controlled Epidural Analgesia for third trimester termination of preganancy analgesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sufentanil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sufentanil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clonidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clonidine
Study: NCT01254448

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Group 1: matching placebo administered once daily for 28 days. Group 2: matching placebo administered once daily for 10 days.
Study: NCT03278548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volulyte 6%
Description: Solution for infusion
Study: NCT01589510

Intervention type: DRUG
Intervention: bimatoprost 0.01% ophthalmic solution
Description: Bimatoprost 0.01% ophthalmic solution (Lumigan® 0.01%) as prescribed by physician per standard practice for up to 14 weeks.
Study: NCT01754675

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Soccer
Description: Watching the soccer match at the time that the favorite team is playing

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Movie
Description: Watching a movie at the time that the favorite team is playing
Study: NCT01098825

Intervention type: OTHER
Intervention: web-based survey
Description: Anonymous web-based survey
Study: NCT02000518

Intervention type: RADIATION
Intervention: external beam radiotherapy
Study: NCT03278548

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ionolyte
Description: Solution for infusion
Study: NCT02563821

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: epidural catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: epidural catheter
Study: NCT02931045

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Comparison of ticagrelor with another antiplatelet drug (clopidogrel)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Comparison of clopidogrel with another antiplatelet drug (ticagrelor)
Study: NCT02742129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized Sodium Nitrite
Description: Inhaled, nebulized inorganic sodium nitrite vs. inhaled, nebulized placebo at a dose of 80 mg (or maximally tolerated dose) administered at a minimum of 4 hours apart, three times per day, during the active part of the day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nebulized Sodium Nitrite
Description: Inhaled, nebulized inorganic sodium nitrite vs. inhaled, nebulized placebo at a dose of 80 mg (or maximally tolerated dose) administered at a minimum of 4 hours apart, three times per day, during the active part of the day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Inhaled, nebulized placebo vs. inhaled, nebulized inorganic sodium nitrite at a dose of 80 mg (or maximally tolerated dose) administered at a minimum of 4 hours apart, three times per day, during the active part of the day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled, nebulized placebo vs. inhaled, nebulized inorganic sodium nitrite at a dose of 80 mg (or maximally tolerated dose) administered at a minimum of 4 hours apart, three times per day, during the active part of the day.
Study: NCT04460781

Intervention type: BIOLOGICAL
Intervention: Flublok Quadrivalent influenza vaccine RIV4
Description: Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Intervention: Standard-dose quadrivalent inactivated influenza vaccine SD-IIV4
Description: Route of administration: Intramuscular
Study: NCT04361500

Intervention type: DEVICE
Intervention: Seraph 100
Description: Seraph 100 therapy during a COVID-19 infection
Study: NCT03856684

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-sampling kit sent at home
Description: Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (with the kit provided) or to perform a pap smear.~When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-sampling kit sent at home + SMS reminder
Description: Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (with the kit provided) or to perform a pap smear.~After 2 months without return, a SMS reminder about the available self-sampling kit is sent to the woman. We call return :~* the receipt of the vaginal self-sample at the laboratory~* the performance of a pap smear~* Information about recent screening test or a cervical screening exclusion reason When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Letter offering a self-sampling kit on request+ SMS reminder
Description: Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (kit provided on request) or to perform a pap smear.~Women are invited to ask the kit online, on our website.~For the women who ask the kit, after 2 months without return, a SMS reminder about the available self-sampling kit is sent to the woman. We call return :~* the receipt of the vaginal self-sample at the laboratory~* the performance of a pap smear~* Information about recent screening test or a cervical screening exclusion reason When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS offering a self-sampling kit on request+ SMS reminder
Description: Selected women receive a SMS inviting them to ask a vaginal self sampling kit to perform a sample at home and send it to a laboratory (kit provided on request).~Women are invited to ask the kit by answering 1 by SMS.~For the women who ask the kit, after 2 months without return, a SMS reminder about the available self-sampling kit is sent to the woman. We call return :~* the receipt of the vaginal self-sample at the laboratory~* the performance of a pap smear~* Information about recent screening test or a cervical screening exclusion reason When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory.
Study: NCT01722565

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic abdominoperineal resection with a lightweight mesh (polypropylene and poliglecaprone 25)
Study: NCT01912274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pracinostat
Description: Elderly newly diagnosed patients will all receive pracinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Elderly newly diagnosed patients will all receive azacitadine
Study: NCT01745211

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 755nm Alexandrite Laser
Description: 755nm Alexandrite laser with array handpiece
Study: NCT02696603

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participant self-assessment surveys
Description: At enrollment, participants are asked to complete a baseline health history and a participant-reported symptom inventory. Thereafter, participants are asked to respond to commonly used questions that assess Parkinson Disease symptoms and quality of life at regular intervals.
Study: NCT04810585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept + FOLFIRI
Description: Day 1. Aflibercept + FOLFIRI~* aflibercept(Zaltrap): 4 mg/kg IV infusion for over 1hr (Do not administer as an IV push or bolus)~* Folinic acid: 400 mg/m2 IV infusion for over 2 hours~* Irinotecan: 150 mg/m2 IV infusion for over 1 hours~* 5-FU: 400 mg/m2 IV bolus injection for over 5 minute~* 5-FU: 2400 mg/m2 IV continuous infusion for 46 hours every 2 weeks until progression disease or death or unacceptable toxicity
Study: NCT04157881

Intervention type: DRUG
Group type: OTHER
Intervention: RABEprazole 20 Mg Oral Delayed Release Tablet
Description: Absorption of APO-Dabigatran measured with and without influence of rabeprazole

Intervention type: DRUG
Group type: OTHER
Intervention: APO-Dabigatran 150mg
Description: Absorption of APO-Dabigatran post single dose

Intervention type: DRUG
Group type: OTHER
Intervention: APO-Dabigatran 150mg
Description: Absorption of APO-Dabigatran post single dose
Study: NCT04865666

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: movr mHealth App
Description: The exercises prescribed through the movr app were accompanied with videos, images, and detailed instructions on how to complete them. These exercises consisted of basic movement and mobility patterns and are designed to promote functional movement. Participants were instructed to complete a total of four 'Minis' and two workout 'Builder' sessions per week. Workout Builders are designed to be longer exercise sessions tailored to the user's desired exercise time (15, 30, 45 or 60 min), equipment available (TRX Band, kettlebell, chin-up bar, dumbbells, foam roller, or none), target body region (lower, upper, or whole body), and specific exercise goal ('get sweaty,' 'build strength,' or 'develop mobility'). Version 3.6 of the movr app was used at the start of data collection and was updated to Version 4.1 over the course of the trial. No significant changes were made to the app or to the exercise prescription functionality throughout those updates.
Study: NCT01778998

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MICS-group
Description: Micro incision cataract surgery is done

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SICS-group
Description: small incision cataract surgery is done

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SICS pre-cut
Description: Small incision cataract surgery with pre-cut is done

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SICS stab-incision
Description: Small incision cataract surgery with stab-incision is done
Study: NCT00844103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8566
Description: 10ml oral solution administered once a day over 10 days. Specific dose will be selected by the safety review committee

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10ml oral solution administered once a day over 10 days.